Literature DB >> 28766246

Can Cardiovascular Epidemiology and Clinical Trials Close the Risk Management Gap Between Diabetes and Prediabetes?

Leigh Perreault1, Kristine Færch2, Edward W Gregg3.   

Abstract

PURPOSE OF REVIEW: We reviewed published literature to determine the relationship between A1c and cardiovascular disease (CVD) and summarize the need and implications for CVD risk reduction with interventions, focusing in the prediabetic A1c range (<6.5%). RECENT
FINDINGS: Strong evidence supports a continuous relationship between A1c and CVD-even below the current levels of A1c-defined prediabetes and after adjustment for known risk factors for CVD. Clinical trials have demonstrated a reduction in CV morbidity and/or mortality when interventions are invoked in the prediabetic A1c range. Guidelines advocating CV risk factor management in prediabetes have not been widely adopted, subsequently leading to comparable coronary heart disease risk between people with prediabetes (HR = 1.9, 95% CI 1.7-2.1 vs normoglycemia) and diabetes itself (HR=2.0, 95% CI 1.8-2.2 vs no diabetes). This review highlights the missed opportunity to utilize multiple risk factor interventions to reduce CVD in high-risk people with prediabetes.

Entities:  

Keywords:  A1c threshold; CVD; Macrovascular disease; Review

Mesh:

Substances:

Year:  2017        PMID: 28766246     DOI: 10.1007/s11892-017-0899-7

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  84 in total

1.  Hyperglycemic crises in patients with diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2001-01       Impact factor: 19.112

2.  HbA1c in type 2 diabetes diagnostic criteria: addressing the right questions to move the field forwards.

Authors:  N Sattar; D Preiss
Journal:  Diabetologia       Date:  2012-03-08       Impact factor: 10.122

3.  The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).

Authors:  A Ramachandran; C Snehalatha; S Mary; B Mukesh; A D Bhaskar; V Vijay
Journal:  Diabetologia       Date:  2006-01-04       Impact factor: 10.122

4.  Prospective study of 352 young patients with chemical diabetes.

Authors:  J B O'Sullivan; C M Mahan
Journal:  N Engl J Med       Date:  1968-05-09       Impact factor: 91.245

5.  Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults.

Authors:  Elizabeth Selvin; Michael W Steffes; Hong Zhu; Kunihiro Matsushita; Lynne Wagenknecht; James Pankow; Josef Coresh; Frederick L Brancati
Journal:  N Engl J Med       Date:  2010-03-04       Impact factor: 91.245

6.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.

Authors:  N Sarwar; P Gao; S R Kondapally Seshasai; R Gobin; S Kaptoge; E Di Angelantonio; E Ingelsson; D A Lawlor; E Selvin; M Stampfer; C D A Stehouwer; S Lewington; L Pennells; A Thompson; N Sattar; I R White; K K Ray; J Danesh
Journal:  Lancet       Date:  2010-06-26       Impact factor: 202.731

7.  Oral glucose-tolerance tests and the diagnosis of diabetes: results of a prospective study based on the Whitehall survey.

Authors:  H A Sayegh; R J Jarrett
Journal:  Lancet       Date:  1979-09-01       Impact factor: 79.321

8.  Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.

Authors:  Walter N Kernan; Catherine M Viscoli; Karen L Furie; Lawrence H Young; Silvio E Inzucchi; Mark Gorman; Peter D Guarino; Anne M Lovejoy; Peter N Peduzzi; Robin Conwit; Lawrence M Brass; Gregory G Schwartz; Harold P Adams; Leo Berger; Antonio Carolei; Wayne Clark; Bruce Coull; Gary A Ford; Dawn Kleindorfer; John R O'Leary; Mark W Parsons; Peter Ringleb; Souvik Sen; J David Spence; David Tanne; David Wang; Toni R Winder
Journal:  N Engl J Med       Date:  2016-02-17       Impact factor: 91.245

9.  Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study.

Authors: 
Journal:  Lancet Diabetes Endocrinol       Date:  2015-09-13       Impact factor: 32.069

10.  Glycated hemoglobin measurement and prediction of cardiovascular disease.

Authors:  Emanuele Di Angelantonio; Pei Gao; Hassan Khan; Adam S Butterworth; David Wormser; Stephen Kaptoge; Sreenivasa Rao Kondapally Seshasai; Alex Thompson; Nadeem Sarwar; Peter Willeit; Paul M Ridker; Elizabeth L M Barr; Kay-Tee Khaw; Bruce M Psaty; Hermann Brenner; Beverley Balkau; Jacqueline M Dekker; Debbie A Lawlor; Makoto Daimon; Johann Willeit; Inger Njølstad; Aulikki Nissinen; Eric J Brunner; Lewis H Kuller; Jackie F Price; Johan Sundström; Matthew W Knuiman; Edith J M Feskens; W M M Verschuren; Nicholas Wald; Stephan J L Bakker; Peter H Whincup; Ian Ford; Uri Goldbourt; Agustín Gómez-de-la-Cámara; John Gallacher; Leon A Simons; Annika Rosengren; Susan E Sutherland; Cecilia Björkelund; Dan G Blazer; Sylvia Wassertheil-Smoller; Altan Onat; Alejandro Marín Ibañez; Edoardo Casiglia; J Wouter Jukema; Lara M Simpson; Simona Giampaoli; Børge G Nordestgaard; Randi Selmer; Patrik Wennberg; Jussi Kauhanen; Jukka T Salonen; Rachel Dankner; Elizabeth Barrett-Connor; Maryam Kavousi; Vilmundur Gudnason; Denis Evans; Robert B Wallace; Mary Cushman; Ralph B D'Agostino; Jason G Umans; Yutaka Kiyohara; Hidaeki Nakagawa; Shinichi Sato; Richard F Gillum; Aaron R Folsom; Yvonne T van der Schouw; Karel G Moons; Simon J Griffin; Naveed Sattar; Nicholas J Wareham; Elizabeth Selvin; Simon G Thompson; John Danesh
Journal:  JAMA       Date:  2014-03-26       Impact factor: 56.272

View more
  1 in total

1.  Regression From Prediabetes to Normal Glucose Regulation and Prevalence of Microvascular Disease in the Diabetes Prevention Program Outcomes Study (DPPOS).

Authors:  Leigh Perreault; Qing Pan; Emily B Schroeder; Rita R Kalyani; George A Bray; Samuel Dagogo-Jack; Neil H White; Ronald B Goldberg; Steven E Kahn; William C Knowler; Nestoras Mathioudakis; Dana Dabelea
Journal:  Diabetes Care       Date:  2019-07-18       Impact factor: 19.112

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.